How to Buy Privia Health Group Stock
Privia Health Group Inc
Privia Health Group, Inc. operates as a national physician-enablement company in the United States.
Privia Health Group stock last closed at $23.48, up 0.3% from the previous day, and has increased 27.61% in one year. It has overperformed other stocks in the Health Information Services industry by 0.99 percentage points. Privia Health Group stock is currently +47.49% from its 52-week low of $15.92, and -9.82% from its 52-week high of $26.04.
At the moment, there are 120.51M shares of PRVA outstanding. The market capitalization of PRVA is $2.83B. In the last 24 hours, 715,311 PRVA shares were traded.
How to Buy Privia Health Group Stock
Wondering how to invest in Privia Health Group stock? Here's how.
- Choose where to buy Privia Health Group stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you figure out where to buy Privia Health Group stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Put funds into your investment account: Pick your payment method and add your info.
- Research Privia Health Group stock: The Privia Health Group ticker symbol is PRVA. Is Privia Health Group stock a good investment? Should you buy shares of PRVA? How do PRVA's underlying business fundamentals look? Do top analysts think Privia Health Group is a good buy? Why has PRVA's stock price moved recently? (Hint: Our stock research website can help you understand if PRVA is a good stock to buy).
- Make your PRVA trade: Decide if you will purchase PRVA shares at the current market price or use a limit order to purchase PRVA stock at a particular price.
- Keep an eye on your PRVA investment: Create a watchlist to watch your new investment in Privia Health Group stock.
Step 1: Choose where to buy Privia Health Group stock
You will need a brokerage account to access the NASDAQ market and buy PRVA shares.
Our favorite brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've selected your brokerage, you need to fill out some personal information so you are able to buy PRVA stock today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to create a new trading account.
- Send your info by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've filled out your info on apps for stock market, you need to deposit funds:
Check out the walkthrough below for more details depositing money into your brokerage account.
Step 4: Research Privia Health Group stock
Once you have selected the best place to buy Privia Health Group stock, it's important to analyze their stock prior to buying, so you can comprehend the risk and upside.
Privia Health Group Metrics
Privia Health Group Overview
WallStreetZen was built to help part-time investors perform better fundamental analysis in less time.
You can see all of the due diligence checks on PRVA's stock page.
Is PRVA stock undervalued or overvalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge PRVA's true value.
Using relative valuations measures:
- PRVA could be overvalued based on its P/E ratio of 195.67x, relative to Health Information Services industry P/E ratio of 40.3x
- PRVA could be overvalued based on its P/B ratio of 4.45x, relative to Health Information Services industry P/B ratio of 3.52x
- PRVA could be overvalued based on its PEG ratio of 3.38x
You can do additional valuation analysis on PRVA's stock here.
PRVA Financial Summary
Passed Health Checks:
- Total PRVA debt is lower than 5 years ago, relative to shareholder equity.
- PRVA's operating cash flow of $109.28M allows it to safely service it's debt of $5.59M.
- PRVA earnings of $25.21M is not enough to cover its interest payments.
- There are more short-term assets than long-term liabilities on the PRVA balance sheet.
- There are more short-term assets than short-term liabilities on the PRVA balance sheet.
Failed Health Checks:
- PRVA has a relatively high debt to equity ratio of 0.71.
- PRVA profit margin has gone down from 1.4% to 0.8% in the past year.
Do Wall Street analysts think it's a good time to buy Privia Health Group stock
Out of 11 sell side analysts who research PRVA, the consensus analyst rating on PRVA is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
Latest PRVA Analyst Recommendations
Richard Close, a bottom 3% analyst from Canaccord Genuity maintains PRVA with a strong buy rating and raises their PRVA price target from $29.00 to $30.00, on Feb 28, 2025.
Sean Wieland, a top 20% analyst from Piper Sandler maintains PRVA with a strong buy rating and raises their PRVA price target from $25.00 to $40.00, on Feb 28, 2025.
Piper Sandler's Sean Wieland raised their price target on Privia Health Group (NASDAQ: PRVA) by 60% from $25 to $40 on 2025/02/28. The analyst maintained their Strong Buy rating on the stock.
Privia Health Group reported its Q4 and FY 2024 earnings.
Wieland colorfully commented that "in the rough sea of VBC (Value-Based Care), Privia Health Group is a rock."
Explaining their stance, the analyst reminded readers that the company was the first in its Primary Care v2.0 class to appreciate the perverse incentives and unit economic risks of full capitation in MA.
Privia Health Group preferred shrewd contracts and hand-picked partnerships to unbridled growth, Wieland continued, and now, on reckoning day for VBC, the company likely feels no pain.
Earnings Report
Privia Health Group reported:
For Q4 2024:
- EPS of $0.03, which missed the Zacks Consensus Estimate of $0.06 but beat Q4 2023's $0.02.
- Revenue of $460.9M, which beat the Zacks Consensus Estimate by 10.37% and Q4 2023's $440.83M.
For FY 2024:
- EPS of $0.78, up from FY 2023's $0.64.
- Revenue of $1.736B, up from FY 2023's $1.658B.
For FY 2025, management guided:
- Revenue of 1.800B to $1.9B.
Management did not provide commentary in its press release.
Jeff Garro, a bottom 8% analyst from Stephens & Co. reiterates PRVA with a strong buy rating and maintains their PRVA price target from $26.00 to $26.00, on Jan 7, 2025.
Tao Qiu, a bottom 13% analyst from Macquarie initiates coverage on PRVA with a buy rating and announces their PRVA price target of $25.00, on Dec 16, 2024.
Lisa Gill, a top 15% analyst from JP Morgan maintains PRVA with a strong buy rating and raises their PRVA price target from $27.00 to $28.00, on Nov 29, 2024.
You can dive deeper into what analysts are projecting on the Privia Health Group stock forecast page.
PRVA Momentum
Is PRVA Growing Revenue?
Last year, PRVA earnings were $14.39M. Over the past five year, PRVA's earnings have gone up by 5.92% per year. This was slower than the Health Information Services industry average of 10.2%.
Last year, PRVA revenue was $1.74B. Over the past five year, PRVA's revenue has gone up by 17.17% per year. This was slower than the Health Information Services industry average of 21.98%.
You can research PRVA's earnings and revenue performance here.
Who is buying/selling PRVA?
Over the last year, insiders at PRVA have bought more shares than they have sold.
David Mountcastle, EVP Chief Financial Officer of PRVA, was the latest PRVA insider to sell. They sold $125,999.40 worth of PRVA shares on Apr 2, 2025.
Learn more about who owns PRVA stock here.
Does PRVA stock generate passive income?
No, Privia Health Group doesn't provide an income stream by paying out dividends.
PRVA Social Trading Data
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Make your PRVA trade
There are two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually fine for most investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at an exact dollar amount limit, use a limit order.
Hit the Open button and eToro will place your order.
If you need more info about buying stocks on eToro, watch the helpful video below:
Step 6: Keep an eye on your PRVA investment
Now that you own some PRVA stock, you'll want to stay up-to-date on your stock purchase.
Put PRVA on a watchlist to monitor your PRVA stock.
PRVA Feed
How to Buy Stock in Privia Health Group
To reiterate, here are the 6 steps for buying Privia Health Group stock:
- Choose where to buy Privia Health Group stock
- Create a brokerage account
- Put funds into your investment account
- Research Privia Health Group stock
- Make your PRVA trade
- Keep an eye on your PRVA investment
If you are looking for a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to track your new investment in Privia Health Group, add PRVA to your watchlist below.
Other Content You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.